Introduction
Diabetes mellitus (DM) is a group of metabolic diseases associated with serious complications such as nephropathy, retinopathy and peripheral neuropathy. Characteristic features of DM include, among others, hyperglycemia and high blood level of argininevasopressin (AVP) (1) (2) (3) (4) (5) . Functional consequences of high AVP level in the blood are unclear.
Besides its well-known antidiuretic and vasoconstrictive actions, AVP has been shown to stimulate liver cells to increase their glucose output. AVP has also been shown to increase hepatic glucose output by stimulating the secretion of glucagon from the pancreatic alpha cells (6) (7) (8) and ACTH from the anterior pituitary (9, 10 ). In addition, there is some evidence that abundant circulating AVP contributes to increased glomerular filtration, albuminuria and renal hypertrophy in DM (11) through its action at V2 receptors in the kidney (12, 13) .
Furthermore, it has been shown that, in rats with partial nephrectomy, the reduction of AVP secretion induced by increased water intake retards the progression of renal failure (14) . Thus, elevated AVP in the blood of DM may contribute to the disease progression (8, 15) and directly drive serious diabetic complications, such as renal failure (11) .
It is unknown why AVP blood level is markedly elevated in DM, although it is thought that hyperglycemia, in the absence of insulin, greatly increases the hormonal output of AVP neurons by stimulating osmoreceptors (5, 16) . In this study, we used the streptozotocin (STZ)-induced DM rat model to measure physiological changes in AVP neurons which could underlie the increased hormonal secretion. Here we present evidence that the Cl -importer NKCC1 is up-regulated and the Cl -extruder KCC2 is down-regulated in AVP neurons, thus making GABA excitatory in these cells and that AVP synthesis in magnocellular neurons in the paraventricular (PVN) and supraoptic nuclei (SON) is enhanced. Together these changes would promote the secretion of AVP neurons and, hence, the elevation of AVP blood level and double-transgenic rats of the Wistar strain (6 weeks of age), which express both AVPenhanced green fluorescent protein (AVP-eGFP) fusion gene and OXT-monomeric red fluorescent protein 1 (OXT-mRFP1) fusion gene (17) were used in this study. They were housed in a 12/12-hour light/dark cycled room for >1 week before being used for experiments and handled as previously described (18) .
DM Model. This model was produced by injecting once the antineoplastic drug STZ to the rat (65 mg/kg body weight, i.p.). Fresh STZ solutions were prepared before injections by dissolving the drug (65 mg) in 10 ml of 50-mM sodium citric acid (pH 4.5 Drugs. We purchased all drugs and chemicals used in this study from Sigma-Aldrich, except for muscimol (Ascent Scientific, Cambridge, MA). VU0463271, CLP257 and CLP290 were gifts (see Acknowledgments).
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Results
STZ treatment is commonly used to produce a DM model. To confirm the effectiveness of our treatment protocol, we compared the STZ-treated Sprague-Dawley rats with vehicle-treated ones with respect to various parameters related to DM ( Table I) . The rats treated with STZ (STZ rats) gained significantly less body weight than the vehicle-treated ones (control rats) in the 3-week interval between treatment and experiment. The glucose concentrations in the blood and CSF and the [Na + ] in the CSF were much higher in the STZ, than control rats, whereas the plasma [Na + ] was slightly but significantly lower in STZ rats.
Consistent with these observations, the plasma and CSF osmolalities were also significantly higher in STZ rats. Lastly, the plasma AVP concentrations of STZ rats were ~12 times higher than those of control animals. Thus, taken together, these results indicate that the STZ treatment produced DM in Sprague-Dawley rats.
GABA is excitatory in most of the AVP neurons of STZ rats.
AVP neurons in the PVN and SON are heavily innervated by GABAergic afferents (20) , which originate from the perinuclear zones in the hypothalamus (20) (21) (22) . Through the GABA A receptor, GABA exerts an excitatory, rather than inhibitory, effect in most AVP neurons of chronically salt-loaded, lactating or hypertensive rats (18, 19, 23, 24) in which AVP secretion is enhanced. Thus, in this study, we examined the possibility that GABA functions as an excitatory neurotransmitter in the AVP neurons of STZ rats as well, which would promote the secretory activities of these cells. To test this hypothesis, we first examined the effects of bath-applied bicuculline (GABA A receptor antagonist, 30 µM) on the single-unit activities of the magnocellular neurons recorded extracellularly in the SON slices of control 8 and STZ rats. In the cells (n=16) of control rats (n=3) bicuculline increased (n=10) or decreased the unit activity (n=6), while in the case of STZ rats (n=3) it decreased the unit activity in all cells (n=16) examined (Figs. 1A and 1B) . Thus, these results supported the notion that, in general, GABA is excitatory in the AVP neurons of STZ rats whereas it is inhibitory in the cells of control rats. To obtain further evidence for this hypothesis, we next at membrane potentials between -50 mV and -170 mV (26, 27) and/or phasic patterns of firing (28) (Suppl. Fig. 1 ). It was confirmed that the recorded PSPs from AVP neurons were GABA A receptor-mediated by the inhibitory effects on these synaptic potentials of bicuculline or gabazine (Suppl. Fig. 2 ). Figs. 1C and 1D illustrate that GABAergic PSPs occurring in most of the AVP neurons of STZ rats were excitatory (i.e., EPSPs), whereas those in the cells of control rats were mostly inhibitory (i.e., IPSPs). This difference in
GABAergic transmission was apparently due to the difference in the reversal potential of GABA A receptor-mediated responses (E GABA ) ( Fig. 1E & 1F) ; in the cells of STZ rats, the E GABA was positive by ~13 mV on average to the action potential threshold, which was around -45 mV, whereas in the cells of control animals, it was negative to the threshold by ~6 mV on average. Collectively, these results indicate that, owing to the depolarizing E GABA shift, of STZ rats (n=3); however, VU0463271 did not significantly affect the E GABA (Fig. 3C, bottom right) and GABAergic PSP profile. Thus, these data, together with the results from the Western blot experiments, indicate that the up-regulation of NKCC1 and the downregulation of KCC2 are the molecular mechanisms which underlie the depolarizing shift of E GABA and the consequent emergence of GABAergic excitation in the AVP neurons of STZ rats.
AVP synthesis is enhanced in the AVP neurons of STZ rats.
The results described above demonstrate that GABAergic inhibition is converted into excitation in the AVP neurons of STZ rats, thus indicating that the process of AVP release is enhanced in these cells. To maintain increased hormone secretion in a given neuron, the synthesis of the hormone, as well as its release process, should be enhanced. To see if AVP synthesis was enhanced in the AVP neurons of STZ rats, we compared the STZ-treated Wistar rats expressing both AVP-eGFP and OXT-mRFP1 fusion genes with the vehicle-treated control animals with respect to the intensities of green and red fluorescence in the SON and the magnocellular division of the PVN. As expected, the green fluorescence intensity was significantly higher in both hypothalamic regions of the STZ rats than the control rats (Figs.
4A and 4B).
On the other hand, red fluorescence intensity was not different between the two rat groups in both the SON and PVN (Figs. 4A and 4C) . Thus, these results indicate that the synthesis of AVP, but not OXT, is enhanced in hypothalamic magnocellular neurosecretory cells of the STZ rats.
Systemic administration of the KCC2 activator CLP290 in the STZ rat lowers AVP and glucose levels in the blood. Page 
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The results presented above indicate that the inhibitory-to-excitatory switch in GABAergic transmission in the AVP neurons of STZ rats, an electrophysiological change that would promote the release of AVP from these cells, arises from the up-regulation of NKCC1
and the down-regulation of KCC2. Thus, we reasoned that the blockade of NKCC1 or the activation of KCC2 might decrease AVP release by preventing the GABAergic excitation of AVP neurons. Moreover, we thought that they might lower the blood glucose level as well since AVP increases the blood sugar by stimulating hepatic gluconeogenesis and glycogenolysis (6) (7) (8) . To see if KCC2 activation in STZ rats can lower the AVP and glucose levels in the blood, we examined the effects on these variables of CLP290, a prodrug of the KCC2 activator CLP257 (32). Before we test the effects of CLP290 on the AVP and glucose levels in the blood, we first investigated whether KCC2 activation with CLP257 prevented slices from the same rat group in E GABA (Fig. 5A) and GABAergic PSP profile (ratio of GABAergic EPSPs vs. IPSPs; 1:8 to 0:11). Therefore, these results indicate that the KCC2 activation with CLP257 prevents GABAergic excitation in the AVP neurons of STZ rats.
Therefore, we continued to examine the effects of CLP290 on AVP and glucose levels in the blood. CLP290 (100 mg/kg body weight) or vehicle (20% HPCD) was injected intraperitoneally 4 h prior to the blood sampling for the measurements of AVP and glucose concentrations. As illustrated in Figures 5B and 5C , CLP290 treatment in STZ rats significantly lowered AVP and glucose levels, while in control rats it resulted in a significant increase in the plasma AVP level without affecting the glucose concentration.
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Discussion
The elevated blood level of AVP in DM can aggravate hyperglycemia (6-9) and contribute to the generation of diabetic nephropathy (11) . Despite such potential significance of high blood level of AVP, the mechanisms underlying the elevation of AVP level have not been fully identified. In the current study, we focused on the possible changes occurring in the AVP neurons that would promote their hormone secretion under disease conditions. Secretion of a neurohormone or neurotransmitter from a neuron involves two processes: the synthesis and release of secreted substance. In mature CNS neurons, the release process is governed by the action potential firing, which is in turn regulated mainly by the balance of excitatory glutamatergic and inhibitory GABAergic transmission. Given that AVP neurons are densely innervated by GABAergic afferents (20) and that GABA functions as excitatory, instead of inhibitory, neurotransmitter in the majority of AVP neurons of chronically saltloaded, lactating or hypertensive rats (18, 19, 23, 24) in which AVP secretion is enhanced, we scrutinized GABAergic transmission in the current study. We found that the E GABA depolarized significantly, and therefore, GABA became excitatory in the majority of AVP neurons of our DM model rats. On the other hand, GABA was mostly inhibitory in the cells of normal (i.e., control) rats, as previously reported (19, 23) . Furthermore, we discovered that the synthesis of AVP is greatly increased in the SON and the magnocellular region of the PVN of DM model rats. Thus, our results suggest that increased secretory activities of AVP neurons, due to the enhancement of AVP synthesis and the modulation of GABAergic transmission, contribute to the escalation of blood level of AVP in DM.
AVP neurons are heavily innervated not only by GABAergic inputs, but also by glutamatergic afferents originating from various brain regions including the organum vasculosum of the lamina terminalis, the subfornical organ and the median preoptic nucleus (33) . In a previous study, Di and Tasker (34) showed that dehydration induced by chronic salt loading, which leads to enhanced AVP secretion, increased EPSC amplitude and frequency in magnocellular neurons of the rat SON. Thus, the increased secretory activities of AVP neurons in DM may depend on the modulation of glutamatergic (as well as GABAergic) transmission. The determination of the importance of glutamatergic transmission for the enhancement of AVP secretion in the present model awaits future studies.
In the current study, we discovered that STZ treatment resulted in the depolarizing shift of E GABA and consequent emergence of GABAergic excitation in AVP but not OXT neurons. This finding contrasts with the observations made in our previous study performed with rats in which E GABA depolarized and GABAergic excitation emerged in both AVP and OXT neurons after chronic salt loading (19) . The absence of such changes in the OXT neurons of DM model rats makes sense because the emergence of GABAergic excitation in this neuronal population would enhance the secretion of OXT, a hormone which is known to stimulate the secretion of atrial natriuretic hormone from the atrium (35) and act directly in the kidney to promote natriuresis (36, 37) . The enhanced secretion of OXT would aggravate the hyponatremia present in these animals. In this study, we found that the intraperitoneal injection of the KCC2 activator CLP290 in STZ-induced DM rats lowered the blood level of AVP by ~50% and glucose by ~15%. These results not only support the notion that the down-regulation of KCC2 is partly responsible for the depolarizing shift of E GABA and the emergence of GABAergic excitation in the AVP neurons of DM model rats (see above), but they also suggest that this drug is an effective means of lowering the blood level of AVP and glucose in DM. The smaller effect of CLP290 on the blood sugar than AVP level may be related to the fact that the effects of AVP on glycogenolysis and gluconeogenesis (7, 8) in the liver are reduced in DM due to the downregulation of hepatic V1a receptors (46, 47) and to the fact that AVP is not the only factor contributing to the escalation of the blood sugar in DM.
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The increase in the plasma AVP level of control rats after CLP290 treatment was an unexpected finding, raising the possibility that non-specific effects on cells other than AVP neurons are involved in CLP290 administration in vivo. However, it seems unlikely that the rise of AVP level resulted from GABAergic excitation in AVP neurons in the light of the observation that the KCC2 activator CLP257 did not depolarize the E GABA in these cells. Also, it is unlikely that the plasma AVP concentration was increased by osmotic stimulation because the intraperitoneally injected drug solution was rather hypoosmotic (~270 mOsm/Kg
In summary, we provide evidence that altered Cl -homeostasis in AVP neurons and the enhanced AVP synthesis in these cells are important changes underlying the increase in the plasma AVP level in DM. With growing evidence that elevated AVP in the DM blood is a risk factor for metabolic disorders (8, 15) and progression of serious diabetic complications like nephropathy (11), future studies evaluating the possible effects of drugs including CLP290 that target Cl -transporters against diabetic complications are warranted. ] measurements were obtained from the tail vein without anesthesia, while the blood samples for plasma osmolality and AVP level measurements were obtained by decapitation under urethane anesthesia (1.25 g/kg body weight, i.p.). In order to prevent clotting and protease action, these samples were collected in 3-ml BD vacutainer containing K 2 -EDTA (Franklin Lakes, NJ) and aprotinin (0.6 TIU/ml blood). The plasma was obtained by centrifuging the blood at 1,600 x g for 15 min at 4º C and used immediately for osmolality measurement or stored in a deep freezer (-80º C) until used for AVP Elisa. CSF samples were obtained through the atlanto-occipital membrane just before the blood sampling by decapitation. 
